Gilead acquired global rights to an oral oncology candidate from China‑based Genhouse Bio in a deal that includes an $80 million upfront payment. Genhouse, which recently filed for an IPO in Hong Kong, will hand over global commercial rights while retaining potential contingent payments tied to development and regulatory milestones. The transaction reflects Big Pharma’s continuing strategy to source mid‑stage assets from Asia and accelerate global development through established commercialization channels. Analysts will watch whether Gilead advances the program through late‑stage trials and how the deal shapes Genhouse’s IPO valuation and pipeline priorities.